Adalimumab

U.S. FDA Approves Cyltezo® (adalimumab-adbm)as First Interchangeable Biosimilar with Humira

Ridgefield, Conn., October 15, 2021 Boehringer Ingelheim announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Cyltezo® (adalimumab-adbm) as the first Interchangeable biosimilar with Humira® (adalimumab). The FDA originally approved Cyltezo® in 2017 for the treatment of multiple chronic inflammatory diseases and this latest approval designates…